Digoxin clinical trials
Digoxin is named as an intervention in 9 current clinical trials in our China, USA, UK, Spain, Italy, Canada, Germany, France, Netherlands, Norway, Japan, South Korea, Australia and Israel registers. 4 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Eli Lilly and Company (2). The most-studied condition is Obesity.
Where Digoxin is approved
All regulators →Of the three regulators tracked here, the first to approve Digoxin was the US, on 16 Nov 1954. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Digoxin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Digoxin works
All drug targets →- Sodium/potassium-transporting ATPase inhibitor InhibitorTarget: Sodium/potassium-transporting ATPase✓ In ChEMBL and the Guide to Pharmacology
- Supraventricular tachycardiaPhase 3
- Atrial flutterPhase 3
- PreeclampsiaPhase 2/3
- Hepatic fibrosisPhase 2
- Actinic keratosisPhase 2
- Amyotrophic lateral sclerosisPhase 2
- Bipolar disorderPhase 2
- Breast cancerPhase 2
- Cirrhosis of liverPhase 2
- Malignant pancreatic neoplasmPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1751, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 4726, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Digoxin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 4 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Digoxin
- ATC code
- C01AA05
- ChEMBL
- CHEMBL1751
- DrugBank
- DB00390
- PubChem CID
- 2724385
- CAS number
- 20830-75-5
- FDA UNII
- 73K4184T59
- Wikidata
- Q422222
- Wikipedia
- Digoxin
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Digoxin
9 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Digoxin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
4 single-substance products containing Digoxin on the HPRA medicines list.
- Lanoxin 250 microgram TabletsAspen Pharma Trading Limited · PA1691/001/004 · Marketed
- Lanoxin PG 50 micrograms/ml ElixirAspen Pharma Trading Limited · PA1691/001/002 · Marketed
- Lanoxin PG 62.5 microgram TabletsAspen Pharma Trading Limited · PA1691/001/003 · Marketed
- Lanoxin 500 micrograms/2 ml Solution for InjectionAspen Pharma Trading Limited · PA1691/001/001 · Not marketed
Supply shortages
No entry for Digoxin in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Digoxin
15 conditionsAll 15 conditions
| Condition (as registered) | Trials |
|---|---|
| Obesity | 2 |
| Alveolar Soft Part Sarcoma | 1 |
| Leiomyosarcoma | 1 |
| Synovial Sarcoma | 1 |
| Soft-Tissue Sarcoma | 1 |
| Urinary Bladder Neoplasms | 1 |
| Neoplasm Metastasis | 1 |
| Ureteral Neoplasms | 1 |
| Healthy | 1 |
| Overweight | 1 |
| Colorectal Carcinoma | 1 |
| Drug Drug Interaction (DDI) | 1 |
| Pharmacokinetics and Pharmacodynamics | 1 |
| Healthy Subjects | 1 |
| Healthy Volunteer | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Digoxin trials
How many clinical trials are testing Digoxin?
9 current trials in our China, USA, UK, Spain, Italy, Canada, Germany, France, Netherlands, Norway, Japan, South Korea, Australia and Israel registers name Digoxin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Digoxin trials recruiting patients?
Yes. 4 of the 9 trials are recruiting: 3 with sites in China, 3 with sites in USA, 2 with sites in UK, 2 with sites in Spain, 2 with sites in Italy, 1 with sites in Canada, 1 with sites in Germany, 1 with sites in France, 1 with sites in Netherlands, 1 with sites in Norway, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Australia and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Digoxin clinical trials?
Eli Lilly and Company (2), Advenchen Laboratories, LLC (1), Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (1) and Fudan University (1), among 8 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Digoxin licensed in Ireland?
Yes. The HPRA medicines list includes 4 single-substance products containing Digoxin, for example Lanoxin 250 microgram Tablets (Aspen Pharma Trading Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Digoxin shortage?
Not in the lists we track: Digoxin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Digoxin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Digoxin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Digoxin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.